-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Recently, it has been a period of intensive disclosure of annual reports by listed pharmaceutical companies
.
At the same time, a large number of companies disclosed their operating data from January to February, which attracted the attention of the industry.
On the whole, these companies basically reported good news
.
Among them, Dongyang Sunshine expects to double its net profit growth
.
On March 10, the company announced the main operating data from January to February 2022, stating that the company will no longer consolidate pharmaceutical assets from December 29, 2021, while the company's non-pharmaceutical industry has maintained a high degree of development.
Prosperous, and achieved good operating results
.
From January to February, the company achieved an operating income of about 1.
9 billion yuan, an increase of about 26% compared with the same period last year; the net profit attributable to the parent company was about 200 million yuan, an increase of 180% compared with the same period last year.
around
.
A number of pharmaceutical companies have performed well and are expected to achieve rapid growth in performance from January to February, including WuXi AppTec, Huitai Medical, Zuoli Pharmaceutical, and Bloomage Bio
.
Specifically, WuXi PharmaTech released an announcement on the main operating data for January to February 2022 on the evening of March 9
.
The announcement stated that since the beginning of the year, the company's business situation has been gratifying.
From January to February 2022, the year-on-year growth rate of orders and sales revenue will exceed 65%
.
The company expects revenue growth of 65-68% year-over-year in the first quarter of 2022
.
Looking forward to the full year, the company's revenue growth is expected to reach 65-70% year-on-year
.
Huitai Medical announced on March 9 the main operating data announcement from January to February 2022.
During the Spring Festival in 2022, the company's product sales momentum is good, the market is showing a positive trend, and it has successfully achieved a "good start"
.
According to the company's preliminary calculation, from January to February 2022, the company will achieve a total operating income of about 156 million yuan, a year-on-year increase of about 70%
.
Zuoli Pharmaceutical announced its performance forecast for the first quarter of 2022 on March 9.
The net profit attributable to the parent is expected to be 67 million yuan to 71 million yuan, a year-on-year increase of 52.
98%-62.
12%
.
It is reported that during the reporting period, the operating income of the company's main products Wuling Capsules, Bailing Tablets and Lingze Tablets all achieved rapid growth
.
Bloomage Bio released the operating data from January to February on March 10.
The announcement stated that the functional skin care products segment still grew strongly
.
According to preliminary calculations, from January to February 2022, the company will achieve a total operating income of about 640 million yuan, a year-on-year increase of about 55%
.
In addition, pharmaceutical companies such as Jiuzhoutong, Meinian Health, Jichuan Pharmaceutical, and Pien Tze Huang also disclosed their operating data from January to February, and their net profit also showed positive growth
.
From the perspective of the industry, listed companies disclose monthly operating data reports, or because of the recent downturn in the stock market, relevant companies hope to boost market confidence
.
Judging from the above-mentioned pharmaceutical companies that have disclosed performance data from January to February, they are mainly concentrated in highly prosperous segments such as CXO, medical beauty, medical devices, and traditional Chinese medicine
.
Among them, CXO's short-term high prosperity has almost become the consensus of the industry.
Judging from the announced 2021 annual results and performance forecast, most CXO companies have increased their net profit attributable to their parent companies, and CXO giants have performed well
.
Among them, the profit growth rate of companies represented by WuXi AppTec, Asymchem, and Proton shares in 2021 will all be between 40% and 75%.
Corresponding to Wind’s consensus forecast in 2022, the company’s valuation is mostly around 40 times
.
Another example is the traditional Chinese medicine sector.
Traditional Chinese medicine has always been an important part of China's pharmaceutical industry.
With the strong support of a series of policies, as well as multiple factors such as pharmaceutical consumption upgrades and valuation advantages, the Chinese medicine industry will usher in a rebound in prosperity since 2021.
According to wind data, the A-share Shenwan Traditional Chinese Medicine Index has risen by 16.
75% in the past year, significantly outperforming the market
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
At the same time, a large number of companies disclosed their operating data from January to February, which attracted the attention of the industry.
On the whole, these companies basically reported good news
.
Among them, Dongyang Sunshine expects to double its net profit growth
.
On March 10, the company announced the main operating data from January to February 2022, stating that the company will no longer consolidate pharmaceutical assets from December 29, 2021, while the company's non-pharmaceutical industry has maintained a high degree of development.
Prosperous, and achieved good operating results
.
From January to February, the company achieved an operating income of about 1.
9 billion yuan, an increase of about 26% compared with the same period last year; the net profit attributable to the parent company was about 200 million yuan, an increase of 180% compared with the same period last year.
around
.
A number of pharmaceutical companies have performed well and are expected to achieve rapid growth in performance from January to February, including WuXi AppTec, Huitai Medical, Zuoli Pharmaceutical, and Bloomage Bio
.
Specifically, WuXi PharmaTech released an announcement on the main operating data for January to February 2022 on the evening of March 9
.
The announcement stated that since the beginning of the year, the company's business situation has been gratifying.
From January to February 2022, the year-on-year growth rate of orders and sales revenue will exceed 65%
.
The company expects revenue growth of 65-68% year-over-year in the first quarter of 2022
.
Looking forward to the full year, the company's revenue growth is expected to reach 65-70% year-on-year
.
Huitai Medical announced on March 9 the main operating data announcement from January to February 2022.
During the Spring Festival in 2022, the company's product sales momentum is good, the market is showing a positive trend, and it has successfully achieved a "good start"
.
According to the company's preliminary calculation, from January to February 2022, the company will achieve a total operating income of about 156 million yuan, a year-on-year increase of about 70%
.
Zuoli Pharmaceutical announced its performance forecast for the first quarter of 2022 on March 9.
The net profit attributable to the parent is expected to be 67 million yuan to 71 million yuan, a year-on-year increase of 52.
98%-62.
12%
.
It is reported that during the reporting period, the operating income of the company's main products Wuling Capsules, Bailing Tablets and Lingze Tablets all achieved rapid growth
.
Bloomage Bio released the operating data from January to February on March 10.
The announcement stated that the functional skin care products segment still grew strongly
.
According to preliminary calculations, from January to February 2022, the company will achieve a total operating income of about 640 million yuan, a year-on-year increase of about 55%
.
In addition, pharmaceutical companies such as Jiuzhoutong, Meinian Health, Jichuan Pharmaceutical, and Pien Tze Huang also disclosed their operating data from January to February, and their net profit also showed positive growth
.
From the perspective of the industry, listed companies disclose monthly operating data reports, or because of the recent downturn in the stock market, relevant companies hope to boost market confidence
.
Judging from the above-mentioned pharmaceutical companies that have disclosed performance data from January to February, they are mainly concentrated in highly prosperous segments such as CXO, medical beauty, medical devices, and traditional Chinese medicine
.
Among them, CXO's short-term high prosperity has almost become the consensus of the industry.
Judging from the announced 2021 annual results and performance forecast, most CXO companies have increased their net profit attributable to their parent companies, and CXO giants have performed well
.
Among them, the profit growth rate of companies represented by WuXi AppTec, Asymchem, and Proton shares in 2021 will all be between 40% and 75%.
Corresponding to Wind’s consensus forecast in 2022, the company’s valuation is mostly around 40 times
.
Another example is the traditional Chinese medicine sector.
Traditional Chinese medicine has always been an important part of China's pharmaceutical industry.
With the strong support of a series of policies, as well as multiple factors such as pharmaceutical consumption upgrades and valuation advantages, the Chinese medicine industry will usher in a rebound in prosperity since 2021.
According to wind data, the A-share Shenwan Traditional Chinese Medicine Index has risen by 16.
75% in the past year, significantly outperforming the market
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
